Matching articles for "prednisolone"
Treatment of Allergic Rhinitis and Allergic Conjunctivitis
The Medical Letter on Drugs and Therapeutics • March 31, 2025; (Issue 1725)
Initial treatment of allergic rhinitis (AR) depends
on the severity of symptoms and whether they are
intermittent or persistent (see Table...
Initial treatment of allergic rhinitis (AR) depends
on the severity of symptoms and whether they are
intermittent or persistent (see Table 1).
Corticosteroids in Community-Acquired Pneumonia
The Medical Letter on Drugs and Therapeutics • January 13, 2020; (Issue 1589)
Recently updated guidelines from the American
Thoracic Society (ATS) and the Infectious Diseases
Society of America (IDSA) address the use of
corticosteroids as an adjunct to antimicrobials for
treatment of...
Recently updated guidelines from the American
Thoracic Society (ATS) and the Infectious Diseases
Society of America (IDSA) address the use of
corticosteroids as an adjunct to antimicrobials for
treatment of community-acquired pneumonia (CAP).
OTC Drugs for Seasonal Allergies
The Medical Letter on Drugs and Therapeutics • April 22, 2019; (Issue 1570)
Patients with seasonal allergies often experience
nasal itching and congestion, sneezing, rhinorrhea,
and itchy, watery eyes. Oral, intranasal, and ophthalmic
preparations are widely available over the...
Patients with seasonal allergies often experience
nasal itching and congestion, sneezing, rhinorrhea,
and itchy, watery eyes. Oral, intranasal, and ophthalmic
preparations are widely available over the counter
(OTC) for relief of symptoms. Prescription products for
management of allergic rhinitis and allergic conjunctivitis
are reviewed separately.
Benralizumab (Fasenra) for Severe Eosinophilic Asthma
The Medical Letter on Drugs and Therapeutics • February 26, 2018; (Issue 1541)
The FDA has approved benralizumab (Fasenra –
AstraZeneca), a humanized monoclonal antibody
selective for the interleukin-5 (IL-5) receptor, for
add-on maintenance treatment of severe asthma in
patients...
The FDA has approved benralizumab (Fasenra –
AstraZeneca), a humanized monoclonal antibody
selective for the interleukin-5 (IL-5) receptor, for
add-on maintenance treatment of severe asthma in
patients ≥12 years old with an eosinophilic phenotype.
Benralizumab is the third anti-IL-5 antibody to be
approved for treatment of severe eosinophilic asthma;
mepolizumab (Nucala) and reslizumab (Cinqair), which
target IL-5 itself, were approved earlier.
Drugs for Asthma and COPD
The Medical Letter on Drugs and Therapeutics • August 1, 2013; (Issue 132)
INHALATION DEVICES — Metered-dose inhalers
(MDIs) require coordination of inhalation with hand-actuation
of the device. Valved holding chambers
(VHCs) or spacers help some patients, especially
young...
INHALATION DEVICES — Metered-dose inhalers
(MDIs) require coordination of inhalation with hand-actuation
of the device. Valved holding chambers
(VHCs) or spacers help some patients, especially
young children and the elderly, use MDIs effectively.
VHCs have one-way valves that prevent the patient
from exhaling into the device, minimizing the need for
coordinated actuation and inhalation. Spacers are
tubes or chambers placed between the canister and a
face mask or mouthpiece, which also avoids the need
to coordinate actuation and inhalation. Both VHCs
and spacers retain the larger particles emitted from the
MDI, decreasing their deposition in the oropharynx
and leading to a higher proportion of small respirable
particles being inhaled.
Drugs for Asthma
The Medical Letter on Drugs and Therapeutics • February 1, 2012; (Issue 114)
Inhalation is the preferred route of delivery for most
asthma drugs. Chlorofluorocarbons (CFCs), which
have ozone-depleting properties, are being phased out
as propellants in metered-dose inhalers....
Inhalation is the preferred route of delivery for most
asthma drugs. Chlorofluorocarbons (CFCs), which
have ozone-depleting properties, are being phased out
as propellants in metered-dose inhalers. Non-chlorinated
hydrofluoroalkane (HFA) propellants, which do
not deplete the ozone layer, are being used instead.
Vigabatrin (Sabril) for Epilepsy
The Medical Letter on Drugs and Therapeutics • February 22, 2010; (Issue 1332)
The FDA has approved vigabatrin (vye gá ba trin; Sabril – Lundbeck) for oral use as add-on therapy for complex partial seizures in adults who are refractory to several antiepileptic drugs and as monotherapy...
The FDA has approved vigabatrin (vye gá ba trin; Sabril – Lundbeck) for oral use as add-on therapy for complex partial seizures in adults who are refractory to several antiepileptic drugs and as monotherapy for infantile spasms. Vigabatrin has been available in other countries for many years. Because of its potential for retinal toxicity, it will be available in the US only through a restricted distribution program called SHARE (Support, Help and Resources for Epilepsy). Prescribers and pharmacists distributing the drug must register, and patients must undergo visual field testing.
Colchicine and Other Drugs for Gout
The Medical Letter on Drugs and Therapeutics • November 30, 2009; (Issue 1326)
Until the recent introduction of febuxostat (Uloric), no new drugs had been marketed for treatment of gout in the past 40 years. Colchicine, which has been available for decades as an unapproved drug, has now...
Until the recent introduction of febuxostat (Uloric), no new drugs had been marketed for treatment of gout in the past 40 years. Colchicine, which has been available for decades as an unapproved drug, has now been approved by the FDA (Colcrys) for treatment and prophylaxis of gout flares. It was approved earlier only in combination with probenecid (Colbenemid, and others). The goals of gout treatment are three-fold: treating acute disease, preventing flares and reducing uric acid stores.
Drugs for Asthma
The Medical Letter on Drugs and Therapeutics • December 1, 2008; (Issue 76)
No truly new drugs have been approved for treatment of asthma since omalizumab (Xolair) in 2003, but some randomized controlled trials of older drugs have been published, and new guidelines have become...
No truly new drugs have been approved for treatment of asthma since omalizumab (Xolair) in 2003, but some randomized controlled trials of older drugs have been published, and new guidelines have become available.
Drugs for Asthma
The Medical Letter on Drugs and Therapeutics • May 1, 2005; (Issue 33)
Patients with mild, infrequent asthma symptoms may require only intermittent, asneeded use of an inhaled short-acting beta2-adrenergic agonist. Use of a short-acting beta2-agonist more than twice weekly, other...
Patients with mild, infrequent asthma symptoms may require only intermittent, asneeded use of an inhaled short-acting beta2-adrenergic agonist. Use of a short-acting beta2-agonist more than twice weekly, other than for exercise-induced bronchospasm, indicates a need for anti-inflammatory treatment. Inhaled corticosteroids are the most effective anti-inflammatory medication; leukotriene modifiers are less effective alternatives. If regular use of an inhaled corticosteroid in a low dose does not prevent symptoms, a long-acting beta2-agonist should be added; addition of a second drug is more effective than raising the dose of the inhaled steroid. A leukotriene modifier can also be used as the second drug. Omalizumab may be considered as adjunctive therapy for patients more than 12 years old who have allergic asthma not controlled by other drugs. A short course of oral corticosteroids may be useful for acute exacerbations. Treatment of acute severe asthma as a medical emergency is not included here; it has been reviewed elsewhere (ER McFadden Jr, Am J Respir Crit Care Med 2003; 168:740).
Generic drugs
The Medical Letter on Drugs and Therapeutics • October 14, 2002; (Issue 1141)
When patents expire on brand-name drugs and generic formulations become available, patients and managed care organizations may express a preference for the lower-cost generics. Are they equivalent to the...
When patents expire on brand-name drugs and generic formulations become available, patients and managed care organizations may express a preference for the lower-cost generics. Are they equivalent to the brand-name product?
Drugs for Asthma
The Medical Letter on Drugs and Therapeutics • October 1, 2002; (Issue 2)
New drug formulations continue to be introduced for the treatment of asthma, and new studies on older drugs continue to change our perspectives on the management of this chronic inflammatory disease. Treatment...
New drug formulations continue to be introduced for the treatment of asthma, and new studies on older drugs continue to change our perspectives on the management of this chronic inflammatory disease. Treatment of asthma in the emergency department or hospital is not addressed here. More information on the diagnosis and treatment of asthma is available from Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma (Bethesda:NIH, 1997 and 2002 update; www.nhlbi.nih.gov).
Prevention and Treatment of Injury from Chemical Warfare Agents
The Medical Letter on Drugs and Therapeutics • January 7, 2002; (Issue 1121)
The recent terrorist attacks on the US have led to many questions about the clinical effects, prevention and treatment of injury caused by chemical warfare...
The recent terrorist attacks on the US have led to many questions about the clinical effects, prevention and treatment of injury caused by chemical warfare agents.